As key mediators of cell-to-cell communication, Exos play important roles in a variety of biological roles and injury repair processes, such as regulating immune response ^[1][30], promoting the repair of traumatic brain injury ^[2][31], and stimulating bone tissue regeneration ^[3][32]. Studies have shown that in the treatment of bone tissue regeneration, MSC-Exos stimulate osteoblast proliferation and angiogenesis and inhibit osteoclast maturation by delivering endogenous cargo ^[4][33]. Since Exos generally have similar therapeutic properties to their parent cells, Exos derived from different MSCs have different effects on bone regeneration and repair ^[5][6][34,35]. Therefore, in the strategy of applying MSC-Exos to bone regeneration, it is important to select an appropriate source of parental cell types ^[7][36].

The sources of parental MSCs of Exos mainly include BMSCs ^[8][12], ADSCs ^[9][13], UCMSCs ^[10][14], iPSCs ^[11][15], etc. As shown in Table 1, among these cells, BMSCs are the most commonly used cell source for tissue engineering ^[12][37]. Numerous studies have shown that BMSC-derived Exos (BMSC-Exos) can stimulate the proliferation and osteogenic differentiation of BMSCs, thereby promoting osteogenesis, angiogenesis, and bone mineralization in critical bone defect models ^[13][38]. Compared with BMSCs, human adipose mesenchymal stem cells (hADSCs), mainly derived from adipose tissue, are easier to obtain. hADSCs are widely distributed in the human body and proliferate rapidly, which is an ideal type of MSC for improving Exos production ^[14][39]. However, compared with BMSCs, hADSCs may have less osteogenic differentiation potential ^[15][40]. Some scholars compared the osteogenic differentiation potential of rat BMSC-Exos and ADSC-derived Exos (ADSC-Exos) in osteogenesis-induced (OI) conditions. The results showed that BMSC-OI-Exos significantly up-regulated the expression of osteogenesis-related genes and proteins, including Col I, Runx2, BSP, OCN, BMPR-IA, and BMPR-II, while ADSC-OI-Exos only up-regulated BSP, BMPR-IA and, BMPR-II, which suggested that ADSC-OI-Exos may have a lower osteoinductive ability compared with BMSC-OI-Exos ^[16][41]. In addition, hADSC-derived Exos (hADSC-Exos) have shown great therapeutic potential in the treatment of ischemic diseases, indicating that hADSC-Exos may also play a potential role in bone regeneration by promoting angiogenesis ^[17][42]. Human umbilical cord mesenchymal stem cells (hUCMSCs) have also attracted much attention in BTE. hUCMSCs are a primitive population of MSCs obtained from Wharton’s jelly, the main component of the human umbilical cord matrix ^[18][43]. hUCMSCs can indirectly promote bone regeneration by inducing angiogenesis rather than directly promoting osteogenic or chondrogenic differentiation. Compared with other MSCs derived from bone marrow or fat, hUCMSCs showed higher pluripotency ^[19][20][44,45] and stronger pro-angiogenesis properties ^[21][46]. In addition, hUCMSCs are derived from human postnatal waste tissues and were abundant in source, which is a rich source without ethical and moral controversies, showing greater clinical potential ^[22][47]. Similar to hUCMSCs, iPSCs also have no immune rejection or ethical issues and can proliferate indefinitely; however, iPSCs may have tumorigenic risks ^[23][48]. In recent years, studies have shown that MSCs derived from iPSCs (iPS-MSCs) have the advantages of both iPSCs and MSCs. iPS-MSCs can maintain their self-renewal ability after 40 passages. Importantly, iPS-MSCs are not tumorigenic ^[24][49]. In the treatment of bone defects, iPS-MSCs show strong proliferative and immunomodulatory abilities to promote bone regeneration ^[11][15]. Exos derived from iPS-MSCs also have similar properties to their parental cells. Therefore, iPS-MSCs are an excellent cell source for Exos to promote bone regeneration ^[25][22]. In addition to the above-mentioned MSCs, some local tissue-derived MSC-Exos also have good application potential. Stem cells from human exfoliated deciduous teeth (SHEDs), which are immature MSCs with multiple differentiation potential, can be easily obtained in a non-invasive way without ethical problems ^[26][50]. Compared with BMSCs, SHEDs have a stronger proliferative capacity due to the abundant secretion of growth factors such as fibroblast growth factor 2 (FGF2) and transforming growth factor-β2 (TGF-β2) ^[27][51]. Moreover, compared with pulp stem cells, SHEDs have a stronger capacity to promote bone mineralization ^[28][52]. SHED-derived Exos, in combination with tricalcium phosphate (β-TCP), have been shown to enhance alveolar bone regeneration by promoting angiogenesis and osteogenesis ^[29][53]. In addition to the source of parental MSCs, the therapeutic effect of Exos may also be influenced by some underlying diseases of the donor. A recent study showed that BMSC-Exos obtained from the T₁DM rat model was significantly less effective in promoting BMSC osteogenic differentiation and endothelial cell angiogenesis than BMSC-Exos obtained from normal rats ^[6][35]. This suggests that Exos from donors with chronic underlying diseases have a poor therapeutic effect, or even the opposite therapeutic effect, which may not be suitable for regenerative medicine ^[30][54]. Further research is needed to explore the potential therapeutic effects of donor-derived Exos in disease states.

The regeneration of critical bone defects caused by bone tumors, injuries, and other bone diseases requires bone grafting to replace the defective bone. EV-mediated BTE therapy has become an attractive bone defect replacement strategy in recent years ^[31][55]. Accumulating studies have shown that EV-loaded hydrogels or scaffolds, alone or in combination, can significantly promote local bone regeneration (as shown in Figure 12).

Hydrogels are physically or chemically cross-linked three-dimensional (3D) hydrophilic polymer networks that can adsorb large amounts of water without being dissolved ^[32][56]. Biomedical hydrogels are structurally similar to the natural extracellular matrix, which have attracted extensive attention in regenerative medicine due to their properties of tissue-like water content, good biocompatibility, and easy implantation. In regenerative medicine, hydrogels, as an effective carrier, are widely used in drug delivery and active molecule encapsulation matrix for tissue repair, including bone tissue repair ^[33][57]. In bone tissue regeneration, biopolymer hydrogels can be injected directly into bone defects and flow over complex and irregular bone surfaces, matching the gaps between implants and randomly shaped defects and increasing the contact area ^[34][58]. In addition, the porous structure of hydrogels can continuously release bioactive factors, including EVs/Exos, which is beneficial for repairing bone defects in BTE ^[34][58]. Studies have shown that Exos coated in biodegradable hydrogels can still exhibit the desired therapeutic effect ^[35][36][59,60]. Hydrogels provide a 3D matrix for Exos that prevents the dispersion of Exos and maintains its local concentration, which enables controlled release of Exos for sustained efficacy. Hydrogel-released Exos at bone defect sites can reduce Exos consumption and ectopic effects to promote angiogenesis and osteogenesis ^[37][61]. Some scholars found gelatin nanoparticle hydrogels combined with hADSC-Exos can accurately transport the hADSC-Exos to the target site and effectively promote bone healing ^[38][62]. In addition, the hydrogel 3D microenvironment can also enhance Exos activity and affect the interaction of EV integrin membrane protein between cells and the cell matrix to promote the proliferation and differentiation of osteoblasts and bone angiogenesis in a bone regeneration environment. Yu et al. ^[39][4] demonstrated that Exos derived from periodontal ligament stem cells (PDLSCs) encapsulated in a hydrogel 3D microenvironment exhibited enhanced osteoinductive ability and could significantly promote bone defect repair in rats. Another study demonstrated alginate hydrogels combined with EVs showed increased interactions with other cells, cell aggregation, and prolonged long-term viability, which in turn promoted osteogenesis ^[37][61]. Therefore, a variety of special properties of hydrogels can be combined with MSC-EVs to effectively treat bone defects.

At present, the commonly used biomedical hydrogels mainly include natural and synthetic polymer hydrogels, such as gelatin, hyaluronic acid hydrogel (HA-gel), chitosan, polyethylene glycol (PEG), etc. ^[40][63]. Compared to natural materials, synthetic polymers have basic structural units, well-defined properties, including porosity and degradation time, and known mechanical properties, making synthetic polymer hydrogels more suitable for specific bone tissue regeneration applications ^[41][64]. In addition, synthetic polymers are suitable delivery vehicles for EVs in bone defect repair due to their reliable source of material, long shelf life, and low risk of immunogenicity ^[42][65]. However, due to their fragile network structure, the mechanical properties, stability, and cell adhesion of traditional hydrogels are usually weak, which hinders their application as bone structural materials ^[43][66]. To overcome this limitation, hydrogels are often modified by chemical, physical, and biological methods to prepare high-performance hydrogels with enhanced mechanical properties, stability, cell adhesion, and other properties ^[40][63]. Ma et al. ^[44][67] used propionic acid (CA) with a catechol group to modify an injectable thermosensitive hydrogel through a covalent bond. The cross-linking network formed by the interaction between the catechol group of CA and the collagen molecules in hydrogels can effectively improve the mechanical properties of hydrogel ^[45][68]. In addition, the combination of two hydrogels to prepare new hydrogels is also a common way of hydrogel modification. Previous studies revealed that the combination of a gelatin derivative, gelatin methacrylate, and a PEG derivative, polyethylene glycol diacrylate, can prepare a hydrogel with good cell adhesion and stronger mechanical properties ^[46][69]. Hydrogels with good performance can be obtained by various methods; however, how to effectively load bioactive molecules such as EVs/Exos into hydrogels and improve their long-term retention at defect sites is also a challenge in BTE. Currently, the commonly used method is to directly mix Exos with hydrogels ^[47][70], which may lead to low loading efficiency, structural destruction of Exos, and hindered osteogenic potential ^[48][71]. Recent studies have demonstrated that substances such as peptides can be used to effectively fix EVs/Exos, showing excellent drug delivery ability, which can effectively deliver EVs/Exos ^[49][72]. Huang et al. ^[50][29] found that integrin membrane proteins in MSC-EVs could combine with collagen and fibronectin-derived peptides secreted by cells. Subsequently, the adhesive peptide (RGD) was added to alginate hydrogels containing EVs overexpressing bone morphogenetic protein 2 (BMP-2) to target cellular integrins. The results showed that EVs could be effectively fixed to hydrogels through the interaction of protein domains on the cell membrane ^[50][29]. In another study, some scholars incorporated Exos into an injectable thermosensitive hydrogel by constructing fusion peptides, which also enhanced the retention of Exos and improved the biological activity of Exos ^[44][67]. The above results indicated that the addition of bioactive substances such as peptides can enhance the fixation and retention of EVs without impairing the structural integrity and biological activity of EVs. This enhanced fixation and retention may prolong the presence of EVs at healing sites, leading to increased efficiency of delivery as well as functionality. It should be noted that the mechanical properties, gelation time, biocompatibility, and biological functions of hydrogels vary due to different raw materials and synthesis conditions in the practical application of hydrogels ^[51][73]. Some studies suggest that chitosan hydrogel has good biocompatibility, hemostasis, and chemical activity ^[52][74], while alginate is a biologically neutral material with adjustable mechanical properties and biodegradation ^[53][75]. In addition, since the efficacy of MSC-EVs encapsulated in hydrogels on bone regeneration largely depends on the design and function of hydrogels, attention should be paid to the different characteristics of hydrogels when they are used as delivery materials ^[51][73]. Zhang et al. ^[54][76] prepared an injectable thermosensitive chitosan hydrogel with good biodegradability and biocompatibility, which can improve the stability and retention of human placental MSC-Exos, and effectively enhance bone regeneration by promoting angiogenesis.

In summary, due to its special structure, hydrogels can effectively fill the bone defect area. When combined with EVs and other bioactive molecules, the porous hydrogels can realize the sustained release of EVs. In addition, on the one hand, effective encapsulation of hydrogels can maintain the concentration of EVs and provide a 3D microenvironment similar to the natural extracellular matrix, enhancing the activity of EVs and promoting injury repair; On the other hand, it reduces the possibility of contact with other tissues during transportation, which improves the accuracy and effectiveness of transportation, thereby maximizing the osteogenic effect of EVs. Traditional hydrogels have shortcomings such as insufficient mechanical properties, stability, and adhesion. Recent studies have found that hydrogels can be modified by adding active substances such as peptide sequences to improve their performance and achieve long-term retention of EVs. In addition, different types of hydrogels should be carefully selected to effectively exert their different properties in BTE. However, when applied to critical bone defects with large distances or poor biomechanical environment, it has to be admitted that the poor mechanical properties of hydrogels still cannot satisfy the effective repair of the damage, which makes the development and application of scaffold materials attract extensive attention in BTE.

In the repair of bone defects, bioactive scaffolds are often used as bridging materials to promote bone regeneration ^[55][9]. BTE scaffolds are not only bioabsorbable and biodegradable but also can provide temporary mechanical support for the bone at the implant site, with good mechanical properties. In addition, scaffolds have a highly porous and 3D structure that ideally mimics the porosity, pore size, and interconnectedness of native bone. This specific structure promotes cell attachment and proliferation, providing space for the growth and vascularization of new tissue ^[56][57][77,78]. Palma et al. ^[58][79] reported the influence of different formulations of bone grafts in providing an adequate scaffold, thus emphasizing the importance of the type of carrier in the three-dimensional distribution of particles and also space provision in new bone formation. The results showed that the lyophilized form carrier created a more homogenous interparticle spacing, allowed a more suitable particle distribution and stabilization, and provided a required space which is crucial for proper cellular and vascular colonization, then promoting a faster bone regeneration with relevant clinical benefits ^[58][79]. Similarly, compared with compacted materials, a biocompatible 3D porous scaffold could ensure a uniform spacing and stable distribution of MSC-EVs ^[59][80]. The pores or the space provision of scaffolds can assure an adequate environment for growth factors and nutrients, realizing the constant flow of nutrients, cells, and growth factors from the outer portion to the core of the scaffold and promoting bone regeneration ^[60][61][81,82]. In addition, scaffold surface porosity and the related micro- and nano-morphology directly influence cell behavior, stimulating proper communication among the resident cells ^[59][62][63][80,83,84]. There is no consensus concerning the more appropriate porosity value or pore size currently. However, when mechanical properties are satisfied, over 90% of studies recommended high porosity values, with a wide range of pore sizes from 10 to at least 200 µm ^[62][64][83,85]. In BTE, bioscaffolds with good mechanical properties provide attachment for osteoblasts, which proliferate and differentiate into osteocytes. Subsequently, the implanted scaffold is gradually degraded and replaced by mature osteocytes, and finally, the typical bone structure is restored ^[65][86]. In addition, specific surfaces of some osteogenesis-induced scaffolds support osteoblastic cell differentiation and the expression of the osteoblastic phenotype ^[66][87]. Studies have shown that the classical β-TCP porous scaffolds have good biocompatibility and are widely used in the clinical application of bone repair and regeneration ^[67][88]. However, various scaffolds, including β-TCP scaffolds, have limited repair capacity for critical bone defects due to a lack of osteoinductive activity ^[68][69][89,90]. Only relying on the scaffold itself as a bone graft material cannot achieve satisfactory bone defect repair ^[56][70][77,91]. Accumulated studies have proved that MSC-EVs can effectively enhance the osteoinductive performance of scaffold materials as bioactive molecules. Therefore, as a bioactive material for carrying MSC-EVs, the combined application of bioscaffolds and MSC-EVs has a better regenerative effect in repairing bone defects ^[25][22]. Zhang et al. ^[25][22] demonstrated for the first time that human iPS-MSC-derived Exos (hiPS-MSC-Exos) can be used in combination with β-TCP to significantly promote osteogenesis in the rat calvarial defect model. Exos loaded on hiPS-MSC-Exos/β-TCP scaffolds are internalized into human bone mesenchymal stem cells (hBMSCs), which can stimulate the proliferation and differentiation of endogenous BMSCs and promote the recruitment of BMSCs to specific sites in bone defects to enhance new bone formation, indicating that Exos can enhance the osteogenic activity of β-TCP, and the potential mechanism of Exos promoting bone regeneration may be the activation of endogenous BMSCs at the bone defect sites. In addition, Xin et al. ^[71][92] demonstrated that hiPS-MSC-Exos/β-TCP combined with scaffolds can effectively promote neovascularization in the osteoporosis rat calvarial defect model, and the area of newly formed vessels increases with the increase of hiPSC-MSC-Exos concentration. Furthermore, MSC-Exos from gums or fat in combination with polymer or polymer/calcium silicate composite scaffolds also enhanced bone regeneration ^[72][73][93,94]. All the above results confirm the potential of MSC-EVs combined with scaffolds in repairing bone defects.

There are various types of scaffolds in BTE, including collagen sponge scaffolds ^[74][95], β-TCP scaffolds ^[25][22], hydroxyapatite (HA) scaffolds ^[10][14], calcium sulfate cement scaffolds ^[75][96], bioactive glass ^[16][41], polycaprolactone (PCL) scaffolds ^[76][97], and other innovative synthetic scaffolds ^[77][19], which should be selected appropriately according to their different properties when applied to the regeneration of bone defects. For example, compared with other bone substitutes, the translucent collagen sponge is an ideal scaffold for the detection of MSC-Exos in periodontal tissue regeneration and is commonly used as a scaffold material for carrying Exos in periodontal defect models ^[78][98]. In addition, native EVs have poor osteoinductive ability. The secretion of EVs and the expression profiles of their intrinsic cargo are influenced by different cellular microenvironments. Different delivery materials or culture conditions can modulate the microenvironment of parental cells and alter the abundance of EV cargo by giving appropriate physical, chemical, and mechanical stimuli, thereby affecting the function of EVs ^[79][80][81][99,100,101]. Therefore, currently, parental MSCs are often pretreated with hypoxia, chemical agents, or cytokines to obtain EVs with enhanced osteoinductive properties ^[82][83][102,103]. The functional engineered EVs prepared by various methods combined with different scaffold materials can effectively promote the repair of bone defects ^[84][85][104,105]. Liang et al. ^[86][106] found that angiogenesis was significantly promoted when dimethyloxalylglycine (DMOG)-pretreated MSC-Exos loaded by classical HA scaffolds in a rat calvarial defect model. DMOG is a small angiogenic molecule that regulates the stability of hypoxia-inducible factor-1α (HIF-1α) by inhibiting proline hydroxylase and can simulate cell hypoxia at normal oxygen levels ^[87][88][107,108]. However, hypoxia can improve the regulatory ability of MSCs to induce angiogenesis, osteogenic differentiation, and anti-apoptosis by activating the expression of HIF-1α, thereby changing the expression profile of MSC-Exo content ^[89][109]. Furthermore, preparing genetically modified hBMSCs by constitutively expressing osteogenic-related genes or proteins is also a common strategy to improve the osteoinductive properties of EVs. The functionally engineered EVs prepared by various methods combined with different scaffold materials can effectively promote the repair of bone defects ^[85][86][105,106]. Huang et al. ^[90][110] generated functionally engineered EVs with enhanced osteoinductive properties by constitutively expressing BMP-2 in hBMSCs, which showed a good effect on bone defect repair. Moreover, Ying et al. ^[91][111] loaded BMSC-Exos carrying mutant HIF-1α (BMSC-Exo-HIF-1α) into β-TCP scaffolds and found that the effect of BMSC-Exo-HIF-1α combined with β-TCP scaffolds in promoting angiogenesis and new bone regeneration was significantly better than that of BMSC-Exos combined with β-TCP scaffolds in the rat calvarial defect model. Although EVs with enhanced osteogenic capacity obtained by various means show good regenerative therapeutic effects, to date, most of the bioactive molecules loaded by carrier systems, including EVs, show explosive release, which may stimulate early bone resorption, leading to brittle bone formation or reduced bone formation, thereby impairing the osteogenic properties of EVs ^[92][112]. Therefore, to achieve the slow and sustained release of EVs required for treatment and improve the efficiency of drug administration, many explorations have been carried out. Through the synthesis of degradable copolymer poly(lactic-co-glycolic acid) (PLGA) and metal-organic frameworks (MOFs), Yue et al. ^[77][19] developed an Exo-functionalized PLGA/Mg-GA MOF (PLGA/Exo-MG-GA MOF) scaffold with a unique nanostructure that achieved the controlled release of cargo, thereby effectively promoting osteogenesis and angiogenesis and alleviating inflammation. In addition, some scholars have explored the application effect of the combination of synthetic scaffolds and reagents. Qayoom et al. ^[75][96] also achieved the controlled release of Exos with long-term effects by using independently synthesized calcium sulfate/nano-hydroxyapatite nano-cement (NC) as the carrier, combined with BMP and zoledronate (ZA), an anti-bone absorption agent. This is attributed to the bionic properties and interaction potential of the NC matrix with BMP and ZA. Previous studies have shown that the explosive release of Exos may be caused by direct adsorption of Exos on the scaffold due to the way of solution infusion. Some scholars believe that the explosive release of Exos may be controlled by surface chemical modification of the scaffold ^[9][71][13,92]. Lin et al. ^[93][113] designed a hierarchical mesoporous bioactive glass (MBG) scaffold, which was inherently osteoinductive and could provide structural bioactivity maintenance, which was applied as a carrier for lyophilized Exos in its micron-sized porosities. Further research found that the controlled release of BMSC-Exos and the maintenance of the biological activity were achieved by lyophilized delivery of BMSC-Exos onto graded MBG scaffolds through the sheltering of micropores on the surface of the scaffolds ^[16][41]. Recent studies have shown that active lyophilized Exos obtained by adding lyoprotectants may enable more stable and lower-cost long-term preservation of Exos during delivery, although this research has not been widely recognized ^[94][114]. The above results demonstrate that controllable release and even long-term preservation of EVs can be achieved by rationally modified scaffolds, thereby effectively improving the bone regeneration effect of EVs.

In summary, loading EVs onto various bioactive scaffold materials is a common strategy for bone defect repair in BTE. However, the osteogenic activity of native EVs may not be sufficient for critical bone defect repair. Engineered EVs, such as pre-treatment of MSCs by genetic engineering, combined with synthetic scaffolds can significantly improve the osteoinductive ability and promote angiogenesis and osteogenesis in bone defect models. In addition, the development of innovative scaffold materials or the application of lyophilized Exos may be a new strategy to achieve effective EV delivery and controlled release to maximize the osteogenic advantages of EVs in BTE. However, it has to be admitted that there are some problems in loading EVs with scaffolds alone: (1) it is still difficult to achieve precise sustained release; (2) the surface environment of the scaffolds may affect the osteogenic properties of EVs; (3) the filling effect and biocompatibility of scaffolds on bone defects are also inferior to hydrogels.

Bioscaffolds with good mechanical and stable properties can fill critical bone defects, while hydrogels with good hydrophilicity can effectively fill complex and irregular bone defects due to their gel-like properties. In addition, hydrogels with good biocompatibility and encapsulation properties have better performance in sustained-release EVs compared to bioscaffolds ^{[32][56][57][95]}[56,77,78,115]. Therefore, the combination of hydrogels and scaffolds can not only provide good mechanical stability but also effectively fill bone defects based on irregular defect shapes and encapsulate EVs for controlled release. Currently, the application of EVs loaded by composite bioscaffolds combined with hydrogels is very attractive in bone regenerative medicine ^[96][116]. A recent study showed that the incorporation of a novel injectable hydrogel, polyethylene glycol maleate citrate (PEGMC), into β-TCP scaffolds effectively enhanced its composite strength and osteoinductive properties ^[97][117]. Subsequently, EVs were loaded into the composite PG/TCP (PEGMC + β-TCP) for application in bone defect repair. It was found that the novel composites loaded with EVs improved the microenvironment of BMSCs and induced high-rate and high-quality bone regeneration by promoting angiogenic activity ^[97][117]. Similarly, in another study, the combined use of HA-Gel hydrogel with a customized nano-hydroxyapatite/poly-ε -caprolactone (nHP) scaffold capable of matching the shape and size of the bone defects also significantly enhanced the angiogenic activity of UCMSC-Exos, demonstrating a strong ability to promote bone formation by inducing angiogenesis ^[10][14]. In this study, both above-mentioned composite scaffolds showed good biocompatibility. In addition, the customized nHP scaffold showed excellent mechanical support properties, while the HA-Gel hydrogel filled the pore structure of the scaffold and achieved the long-term sustained release of UCMSC-Exos. Moreover, to achieve the sustained release of Exos without compromising its biological activity, Swanson et al. ^[98][118] developed a PLGA-PEG-PLGA hydrogel microsphere as an Exos delivery system. Further, Exo-loaded PLGA-PEG-PLGA hydrogel microspheres were filled on poly (L-lactic acid) (PLLA) scaffolds, and it was found that the activity of Exos was not impaired and the repair of rat calvarial defects was significantly promoted. In addition, some studies have found that the new composite material obtained by the combination of solid scaffold materials and hydrogels not only has better mechanical properties but also shows some other unique properties such as self-healing ^[99][119]. Self-healing materials can repair themselves in a short time after being damaged, which can prevent the inhibitory effect of soft tissue infiltration on bone regeneration, thereby ultimately promoting bone damage repair ^[100][120]. Li et al. ^[22][47] successfully prepared a self-healing material (CHA/SF/GCS/DF-PEG) with good mechanical properties and plasticity by using CHA as the main component of the bone graft material, combined with silk fibroin (SF), glycol chitosan (GCS) and difunctionalized polyethylene glycol (DF-PEG). The CHA/SF/GCS/DF-PEG composite material is a promising scaffold for Exos because of its ideal structure and physical properties. The combined application of UCMSC-Exos with this composite material can effectively repair bone defects in rats by increasing BMP-2 and collagen deposition and promoting angiogenesis ^[22][47]. In addition, Liu et al. ^[95][115] prepared a composite hydrogel system with good adhesion and antibacterial properties modified by zeolitic imidazolate framework-8 (ZIF-8) nanoparticles, which can enhance the stability of the implanting environment after bone transplantation and promote bone repair. As a key member of MOFs, nanoscale ZIF-8, which sustainably releases Zn²⁺ and plays an active role in osteogenesis, angiogenesis, and antibacterial processes, is an effective modified material in BTE ^[101][102][121,122].

In summary, the combined application of hydrogels and scaffolds can obtain a composite bone graft material with good mechanical properties, biocompatibility, and encapsulation ability, which effectively makes up for the deficiency of hydrogels or scaffolds alone (As shown in Table 2). The combined application of the two materials, on the one hand, can provide the mechanical properties required for bone defect repair and fill critical bone defects with high stability. On the other hand, it can enhance the activity of EVs and make it possible to realize efficient delivery, long-term preservation, and sustained release of EVs, which is also of great significance for the effective repair of bone defects. In addition, the new graft material obtained by combining the hydrogels with the scaffolds also exhibits good self-healing, adhesion, and antibacterial properties, as well as other properties that are beneficial to the repair of bone defects. However, at present, the research on the application of complex composite materials in bone defect repair is insufficient due to the variety and complexity of raw materials. It should be noted that the above-mentioned new composite materials cannot be directly used for the treatment of clinical bone defects due to the high cost and complicated preparation process. Further research is needed to develop a low-cost and high-efficiency composite delivery system to deliver EVs in BTE.